前列腺动脉栓塞（PAE）在世界范围内越来越多地用于治疗因良性前列腺梗阻（BPO）导致的下尿路症状（LUTS），然而，对于患有前列腺癌（PCa）的患者，PAE的作用尚不明确。本系统回顾总结了关于患有PCa患者的PAE的肿瘤学和功能性结果方面的当前可用文献。 根据偏好报告系统性回顾和Meta分析（PRISMA）的建议进行了系统回顾。在Medline、Embase和York CRD中进行了相关文献的系统搜索，时间跨度是1985年至2022年。使用ROBINS工具进行了风险偏倚和混杂因素评估。本系统回顾包括13个试验（12个病例系列和一个使用犬模型的动物实验）。其中4项研究采用前瞻性研究设计。所有研究的偏倚风险均被评为中度至严重。对于PCa患者的PAE似乎是一种安全且有效的程序，可改善LUTS。尽管在不同的局部或晚期PCa处理场景中已经证明了PAE的可行性，但由于肿瘤反应的不可靠性和缺乏包括长期随访的受控试验，肿瘤学的益处仍存在争议。我们调查文献，以确定PAE在患有前列腺癌的患者中的作用，涉及肿瘤学和功能性结果。结果表明，与早期报道的PAE患有良性前列腺增生症下尿路症状相比，PAE在功能结果方面具有类似的安全性和有效性。 PAE在肿瘤学结果方面的作用需要进一步评估。版权所有2023年欧洲泌尿科学会。由爱思唯尔 B.V.出版。保留所有权利。

Prostatic artery embolization (PAE) is increasingly performed worldwide for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). In contrast, the role of PAE in patients with prostate cancer (PCa) is unclear.This systematic review summarizes the current available literature on PAE in patients with PCa regarding oncological and functional outcome.A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) recommendations. A structured search for the relevant literature from 1985 to 2022 was performed in Medline, Embase, and York CRD. Risk of bias and confounding assessments were performed using the ROBINS tool.Thirteen trials (12 case series and one animal study using a canine model) were included in this systematic review. Four studies had a prospective study design. The risk of bias was rated moderate to serious in all the studies.PAE in patients with PCa seems to be a safe procedure and effective regarding the improvement of LUTS. Despite PAE having been shown to be feasible in different treatment scenarios of localized or advanced PCa, the oncological benefits are debatable due to an unreliable tumor response and a lack of controlled trials including long-term follow-up.We investigated the literature to determine the role of prostatic artery embolization (PAE) in patients with prostate cancer regarding oncological and functional outcomes. The results suggest a similar safety profile and efficacy in terms of functional outcomes to those reported earlier for PAE in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. The role of PAE regarding oncological outcomes has to be assessed further.Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.